Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients.

Garcilazo-Reyes Y, Alentorn A, Duran-Pena A, Hoang-Xuan K, Houillier C.

Curr Treat Options Neurol. 2019 Jul 19;21(8):39. doi: 10.1007/s11940-019-0578-x. Review.

PMID:
31324993
2.

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K.

Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3.

PMID:
31279304
3.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
4.

Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.

PMID:
30890548
5.

Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.

Le M, Garcilazo Y, Ibáñez-Juliá MJ, Younan N, Royer-Perron L, Benazra M, Mokhtari K, Houillier C, Hoang-Xuan K, Alentorn A.

Oncologist. 2019 Mar 13. pii: theoncologist.2018-0629. doi: 10.1634/theoncologist.2018-0629. [Epub ahead of print]

PMID:
30867243
6.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
7.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C.

Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.

PMID:
30698644
8.

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.

Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E.

Ann Hematol. 2019 Apr;98(4):915-922. doi: 10.1007/s00277-018-3564-6. Epub 2018 Dec 7.

PMID:
30535802
9.

Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination.

Costopoulos M, Kim R, Choquet S, Maloum K, Houillier C, Algrin C, Settegrana C, Villemonteix J, Brissard M, Quiney C, Bernard S, Davi F, Thieblemont C, Hoang-Xuan K, Leblond V, Merle-Beral H, Le Garff-Tavernier M.

Semin Hematol. 2018 Oct;55(4):179-181. doi: 10.1053/j.seminhematol.2017.06.005. Epub 2017 Jul 6.

PMID:
30502843
10.

CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.

Di Stefano AL, Savatovsky J, Feuvret L, Villa C, Reina V, Pha M, Houillier C, Berzero G, Idbaih A, Psimaras D.

Neuro Oncol. 2019 Jan 1;21(1):139-141. doi: 10.1093/neuonc/noy168. No abstract available.

PMID:
30476174
11.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

12.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

13.

Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, Rahimian A, Lemoine F, de la Grange P, Guégan J, Bielle F, Polivka M, Adam C, Meyronet D, Figarella-Branger D, Villa C, Chrétien F, Eimer S, Davi F, Rousseau A, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K, Alentorn A.

Neuro Oncol. 2018 Jul 5;20(8):1092-1100. doi: 10.1093/neuonc/noy019.

14.

Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management.

Vecht C, Royer-Perron L, Houillier C, Huberfeld G.

Curr Pharm Des. 2017;23(42):6464-6487. doi: 10.2174/1381612823666171027130003.

PMID:
29076421
15.

Optic Nerve Infiltration in Primary Central Nervous System Lymphoma.

Ahle G, Touitou V, Cassoux N, Bouyon M, Humbrecht C, Oesterlé H, Baraniskin A, Soussain C, Nguyen-Them L, Gaultier C, Hoang-Xuan K, Houillier C.

JAMA Neurol. 2017 Nov 1;74(11):1368-1373. doi: 10.1001/jamaneurol.2017.2545.

16.

Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.

Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G.

J Neurooncol. 2017 Jul;133(3):603-607. doi: 10.1007/s11060-017-2473-1. Epub 2017 May 10.

PMID:
28492978
17.

High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.

Bone Marrow Transplant. 2017 Aug;52(8):1113-1119. doi: 10.1038/bmt.2017.23. Epub 2017 Apr 24.

18.

Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K.

J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.

PMID:
28432587
19.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

20.

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C.

Neurology. 2017 Jan 3;88(1):101-102. doi: 10.1212/WNL.0000000000003420. Epub 2016 Nov 18. No abstract available.

PMID:
27864520
21.

The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.

Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C; French LOC Network for CNS Lymphoma.

Eur J Cancer. 2016 Jul;61:69-76. doi: 10.1016/j.ejca.2016.03.080. Epub 2016 May 5.

PMID:
27156226
22.

Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.

Nguyen DT, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V.

Ophthalmology. 2016 Sep;123(9):2047-50. doi: 10.1016/j.ophtha.2016.03.043. Epub 2016 Apr 29. No abstract available.

PMID:
27137876
23.

[Primary central nervous system lymphoma].

Royer-Perron L, Hoang-Xuan K, Houillier C.

Rev Prat. 2016 Apr;66(4):419-422. French.

PMID:
30512707
24.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

25.

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.

Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.

PMID:
26688235
26.

Prevalence of hepatitis B virus in primary central nervous system lymphoma.

Faivre G, Thibault V, Tanguy ML, Leblond V, Choquet S, Soussain C, Gonzalez-Aguilar A, Sierra del Rio M, Houillier C, Hoang-Xuan K, Idbaih A.

J Neurooncol. 2015 Oct;125(1):219-21. doi: 10.1007/s11060-015-1879-x. Epub 2015 Aug 14. No abstract available.

PMID:
26272598
27.

TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.

Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K.

Acta Neuropathol. 2015 Sep;130(3):439-40. doi: 10.1007/s00401-015-1461-9. Epub 2015 Jul 21. No abstract available.

PMID:
26195323
28.

Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Damaj G, Ivanoff S, Coso D, Ysaebert L, Choquet S, Houillier C, Parcelier A, Abarah W, Marjanovic Z, Gressin R, Garidi R, Diouf M, Gac AC, Dupuis J, Troussard X, Morschhauseur F, Ghesquières H, Soussain C; LYSA and LOC network, France.

Haematologica. 2015 Sep;100(9):1199-206. doi: 10.3324/haematol.2015.126110. Epub 2015 Jul 16.

29.

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A.

Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.

30.

Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.

Houillier C, Choquet S, Touitou V, Martin-Duverneuil N, Navarro S, Mokhtari K, Soussain C, Hoang-Xuan K.

Neurology. 2015 Jan 20;84(3):325-6. doi: 10.1212/WNL.0000000000001158. Epub 2014 Dec 19. No abstract available.

PMID:
25527263
31.

Mutational analysis of primary central nervous system lymphoma.

Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K.

Oncotarget. 2014 Jul 15;5(13):5065-75.

32.

[Primary CNS lymphoma--an update].

Soussain C, Houillier C, Choquet S, Hoang-Xuan K.

Bull Cancer. 2014 Mar;101(3):314-24. doi: 10.1684/bdc.2014.1909. Review. French.

PMID:
24691194
33.

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C.

Br J Clin Pharmacol. 2014 Aug;78(2):329-42. doi: 10.1111/bcp.12326.

34.

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.

Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes JR, Imperiale D, Cesaro P, Buffa C, Aucan C, Lucca U, Peckeu L, Suardi S, Tranchant C, Zerr I, Houillier C, Redaelli V, Vespignani H, Campanella A, Sellal F, Krasnianski A, Seilhean D, Heinemann U, Sedel F, Canovi M, Gobbi M, Di Fede G, Laplanche JL, Pocchiari M, Salmona M, Forloni G, Brandel JP, Tagliavini F.

Lancet Neurol. 2014 Feb;13(2):150-8. doi: 10.1016/S1474-4422(13)70307-7. Epub 2014 Jan 8.

PMID:
24411709
35.

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy.

Ducray F, Kaloshi G, Houillier C, Idbaih A, Ribba B, Psimaras D, Marie Y, Boisselier B, Alentorn A, Dainese L, Navarro S, Mokhtari K, Sanson M, Hoang-Xuan K, Delattre JY.

J Neurooncol. 2013 Nov;115(2):261-5. doi: 10.1007/s11060-013-1224-1. Epub 2013 Aug 17.

PMID:
23955572
36.

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K.

Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.

37.

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V.

Haematologica. 2012 Nov;97(11):1751-6. doi: 10.3324/haematol.2011.060434. Epub 2012 May 11.

38.

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2012 May;14(5):667-73. doi: 10.1093/neuonc/nos070. Epub 2012 Apr 4.

39.

[Management of primary central nervous system lymphoma].

Gonzalez-Aguilar A, Houillier C, Soussain C, Hoang-Xuan K.

Rev Neurol (Paris). 2011 Oct;167(10):721-8. doi: 10.1016/j.neurol.2011.08.004. Epub 2011 Sep 8. Review. French.

PMID:
21906768
40.

Prophylactic intrathecal chemotherapy in primary CNS lymphoma.

Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K.

J Neurooncol. 2012 Jan;106(1):143-6. doi: 10.1007/s11060-011-0649-7. Epub 2011 Jul 8.

PMID:
21739169
41.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
42.

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.

de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M.

J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):240-6. doi: 10.1136/jnnp.2010.207183. Epub 2010 Aug 27.

43.

Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.

Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K.

J Neurooncol. 2010 Dec;100(3):439-41. doi: 10.1007/s11060-010-0197-6. Epub 2010 May 13.

PMID:
20464625
44.

Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.

Houillier C, Mokhtari K, Carpentier C, Crinière E, Marie Y, Rousseau A, Kaloshi G, Dehais C, Laffaire J, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neuro Oncol. 2010 Jan;12(1):2-6. doi: 10.1093/neuonc/nop002. Epub 2009 Oct 15.

45.

Supratentorial low-grade gliomas in older patients.

Kaloshi G, Psimaras D, Mokhtari K, Dehais C, Houillier C, Marie Y, Laigle-Donadey F, Taillibert S, Guillevin R, Martin-Duverneuil N, Sanson M, Hoang-Xuan K, Delattre JY.

Neurology. 2009 Dec 15;73(24):2093-8. doi: 10.1212/WNL.0b013e3181c6781e. Epub 2009 Nov 11.

PMID:
19907009
46.

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M.

Cancer. 2006 May 15;106(10):2218-23.

47.

Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.

Roy DC, Ouellet S, Le Houillier C, Ariniello PD, Perreault C, Lambert JM.

J Natl Cancer Inst. 1996 Aug 21;88(16):1136-45.

PMID:
8757193
48.

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.

Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J.

J Clin Immunol. 1995 Jan;15(1):51-7.

PMID:
7539011

Supplemental Content

Loading ...
Support Center